Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M1 positive allosteric modulator (Suven Life Sciences)
- Development stage
- Preclinical
- Lead developer
- Suven Life Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Suven Life Sciences is developing a small molecule positive allosteric modulator (PAM) of the muscarinic M1 receptor for the treatment of gastrointestinal disorders. Currently in the lead optimization stage of preclinical development, this program aims to leverage the role of M1 receptors in regulating gastrointestinal motility and secretions. Unlike orthosteric agonists, which bind to the same site as the endogenous neurotransmitter acetylcholine and can lead to receptor desensitization or off-target effects, PAMs bind to a distinct allosteric site. This binding enhances the receptor's affinity or efficacy for acetylcholine, potentially providing a more physiological and selective therapeutic effect. This approach is intended to address various gastrointestinal conditions where cholinergic signaling is impaired, while potentially minimizing side effects associated with non-selective muscarinic activation.
- Other names
- M1 PAMM-1 PAMM 1 PAM
02
Targets
M1 (Muscarinic acetylcholine receptor M1)
Beyond the preview
Go deeper on M1 positive allosteric modulator (Suven Life Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M1 positive allosteric modulator (Suven Life Sciences).